207 related articles for article (PubMed ID: 19535993)
1. Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions.
Waxman EA; Covy JP; Bukh I; Li X; Dawson TM; Giasson BI
J Neuropathol Exp Neurol; 2009 Jul; 68(7):785-96. PubMed ID: 19535993
[TBL] [Abstract][Full Text] [Related]
2. LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions.
Huang Y; Song YJ; Murphy K; Holton JL; Lashley T; Revesz T; Gai WP; Halliday GM
Acta Neuropathol; 2008 Dec; 116(6):639-46. PubMed ID: 18936941
[TBL] [Abstract][Full Text] [Related]
3. Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease.
Higashi S; Moore DJ; Yamamoto R; Minegishi M; Sato K; Togo T; Katsuse O; Uchikado H; Furukawa Y; Hino H; Kosaka K; Emson PC; Wada K; Dawson VL; Dawson TM; Arai H; Iseki E
J Neuropathol Exp Neurol; 2009 Sep; 68(9):994-1005. PubMed ID: 19680143
[TBL] [Abstract][Full Text] [Related]
4. Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease.
Qing H; Zhang Y; Deng Y; McGeer EG; McGeer PL
Biochem Biophys Res Commun; 2009 Dec; 390(4):1229-34. PubMed ID: 19878656
[TBL] [Abstract][Full Text] [Related]
5. LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models.
Guerreiro PS; Huang Y; Gysbers A; Cheng D; Gai WP; Outeiro TF; Halliday GM
J Mol Med (Berl); 2013 Apr; 91(4):513-22. PubMed ID: 23183827
[TBL] [Abstract][Full Text] [Related]
6. Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies.
Uryu K; Richter-Landsberg C; Welch W; Sun E; Goldbaum O; Norris EH; Pham CT; Yazawa I; Hilburger K; Micsenyi M; Giasson BI; Bonini NM; Lee VM; Trojanowski JQ
Am J Pathol; 2006 Mar; 168(3):947-61. PubMed ID: 16507910
[TBL] [Abstract][Full Text] [Related]
7. G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.
Volpicelli-Daley LA; Abdelmotilib H; Liu Z; Stoyka L; Daher JP; Milnerwood AJ; Unni VK; Hirst WD; Yue Z; Zhao HT; Fraser K; Kennedy RE; West AB
J Neurosci; 2016 Jul; 36(28):7415-27. PubMed ID: 27413152
[TBL] [Abstract][Full Text] [Related]
8. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.
Lin X; Parisiadou L; Gu XL; Wang L; Shim H; Sun L; Xie C; Long CX; Yang WJ; Ding J; Chen ZZ; Gallant PE; Tao-Cheng JH; Rudow G; Troncoso JC; Liu Z; Li Z; Cai H
Neuron; 2009 Dec; 64(6):807-27. PubMed ID: 20064389
[TBL] [Abstract][Full Text] [Related]
9. FBXO7 immunoreactivity in α-synuclein-containing inclusions in Parkinson disease and multiple system atrophy.
Zhao T; Severijnen LA; van der Weiden M; Zheng PP; Oostra BA; Hukema RK; Willemsen R; Kros JM; Bonifati V
J Neuropathol Exp Neurol; 2013 Jun; 72(6):482-8. PubMed ID: 23656991
[TBL] [Abstract][Full Text] [Related]
10. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective.
Tanaka M; Kim YM; Lee G; Junn E; Iwatsubo T; Mouradian MM
J Biol Chem; 2004 Feb; 279(6):4625-31. PubMed ID: 14627698
[TBL] [Abstract][Full Text] [Related]
11. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.
Alegre-Abarrategui J; Ansorge O; Esiri M; Wade-Martins R
Neuropathol Appl Neurobiol; 2008 Jun; 34(3):272-83. PubMed ID: 17971075
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and pathological characterization of Lrrk2.
Giasson BI; Covy JP; Bonini NM; Hurtig HI; Farrer MJ; Trojanowski JQ; Van Deerlin VM
Ann Neurol; 2006 Feb; 59(2):315-22. PubMed ID: 16437584
[TBL] [Abstract][Full Text] [Related]
13. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies.
Perry G; Zhu X; Babar AK; Siedlak SL; Yang Q; Ito G; Iwatsubo T; Smith MA; Chen SG
Neurodegener Dis; 2008; 5(3-4):222-4. PubMed ID: 18322396
[TBL] [Abstract][Full Text] [Related]
14. GTP-binding inhibitors increase LRRK2-linked ubiquitination and Lewy body-like inclusions.
Thomas JM; Wang X; Guo G; Li T; Dai B; Nucifora LG; Nucifora FC; Liu Z; Xue F; Liu C; Ross CA; Smith WW
J Cell Physiol; 2020 Oct; 235(10):7309-7320. PubMed ID: 32180220
[TBL] [Abstract][Full Text] [Related]
15. LRRK2 and neurodegeneration.
Santpere G; Ferrer I
Acta Neuropathol; 2009 Mar; 117(3):227-46. PubMed ID: 19142648
[TBL] [Abstract][Full Text] [Related]
16. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
Daher JP; Abdelmotilib HA; Hu X; Volpicelli-Daley LA; Moehle MS; Fraser KB; Needle E; Chen Y; Steyn SJ; Galatsis P; Hirst WD; West AB
J Biol Chem; 2015 Aug; 290(32):19433-44. PubMed ID: 26078453
[TBL] [Abstract][Full Text] [Related]
17. Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.
Daher JP; Pletnikova O; Biskup S; Musso A; Gellhaar S; Galter D; Troncoso JC; Lee MK; Dawson TM; Dawson VL; Moore DJ
Hum Mol Genet; 2012 Jun; 21(11):2420-31. PubMed ID: 22357653
[TBL] [Abstract][Full Text] [Related]
18. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA
J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595
[TBL] [Abstract][Full Text] [Related]
19. α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.
Covy JP; Giasson BI
Neurotoxicology; 2011 Oct; 32(5):622-9. PubMed ID: 21238487
[TBL] [Abstract][Full Text] [Related]
20. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R
Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]